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A BST R AC T   
 
Aim: To evaluate the role of N-terminal pro b-type natriuretic peptide (NT-pro-BNP) in the 
evaluation of hypervolemia in chronic kidney disease (CKD) and its relationship with CKD. 
Methods: Sixty compensated chronic kidney disease patients enrolled in this study. NT-pro BNP 
levels and other routine biochemical laboratory parameters are studied. The associations between 
results were analyzed.  
Results: NT-pro BNP levels were correlated with urea (r = 0.66, p <0.01), creatinine (r = 0.69, p 
<0.01) and phosphorus (r = 0.36, p <0.01) values and were negative correlated with hemoglobin (r 
= -0.32, p = 0.01), hematocrit (r = -0.36, p <0.01), albumin (r = -0.29, p = 0.02) and glomerular 
filtration rate (GFR) values (r = -0.35, p <0.01). 
Conclusion: The positive correlation between NT-pro BNP levels and urea and creatinine values in 
our study and the negative correlation with GFR support that the severity of hypervolemia increases 
as the CKD stage progresses. BNP and NT-pro BNP are strong predictors of all-cause cardiovascular 
mortality in asymptomatic CKD patients. In the light of all these data, it is possible to suggest that 
NT-pro BNP is associated with hypervolemia and therefore increased cardiovascular mortality in 
subjects with CKD. 
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Introduction 
Chronic kidney disease (CKD) is a disease that 
causes significant morbidity and mortality and 
associated cardiovascular diseases are common 
[1]. Left ventricular hypertrophy (LVH), one of 
the cardiovascular problems, is a strong 
predictor of mortality in CKD [2,3]. Therefore, 
early detection of LVH in this population is of 
great importance in preventing mortality and in 
determining CVD risk. LVH is caused by 
prolonged exposure to increased volume load in 
CKD patients and can be detected by 
echocardiography. However, some serum 
markers have been shown to play a role in 
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determining LVH. For example, the N-terminal 
pro-brain natriuretic peptide (NT-pro BNP) has 
been reported in many studies as an important 
predictor of LVH in CKD patients [4-7]. 
Increased extracellular volume, myocardial 
strain and increased left ventricular pressure are 
among the main causes of elevation of NT-pro 
BNP levels in CKD patients [8]. This hormone 
is a member of the family of natriuretic 
peptides, known as vasoactive hormones, and 
when activated via neurohumoral pathways, 
plays a role in regulating blood pressure and 
maintaining volume balance by acting directly 
on the kidneys and systemic vessels [9,10]. 
In the light of current literature, in this study, 
we aimed to evaluate the role of NT-pro BNP 
in the evaluation of hypervolemia in CKD and 
its relationship with CKD. 
 
Materials and Methods 
This prospective study was conducted after 
approval by the local ethics committee 
(Decision no: B.30.2. ABÜ.0.20.05.04-
050.01.04-08). Patients who were referred to 
our Internal Medicine-Nephrology clinic and 
diagnosed as compensated chronic renal failure 
were included in the study on a voluntary basis. 
Laboratory parameters were evaluated with 
blood samples taken at least eight hours after 
fasting were taken according to routine 
procedures in patients with compensated 
chronic renal failure. Complete blood count 
parameters were recorded on Mindrey BC-5380 
analyzer; Glucose, urea, creatinine, sodium, 
potassium, total protein, albumin, calcium, 
phosphorus, parathormone, C-reactive protein 
(CRP) parameters were studied in Abbott C-
8000 clinical chemistry autoanalyser. Plasma 
NT-pro BNP measurements; 
Electrochemiluminescence immunoassay 
method was used with Elecsys 2010 analyzer. 
Cockcroft-Gault formula, which is the most 
commonly used glomerular filtration rate 
(GFR) in clinical practice for the determination 
of CKD stage [Creatinine clearance = (140-
Age) x (Ideal weight) (ml / min) / Serum 
creatinine (mg / dl) X 72 (female x 0.85)] was 
used [11]. 
Exclusion criteria were follows: Patients with 
congestive heart failure, heart valve diseases, 
coronary artery disease, cardiac operation 
history or cardiac pacemaker, cardiomyopathy, 
sick sinus syndrome, chronic obstructive 
pulmonary disease, morbidly obese and 
overweight, hypo / hyperthyroidism and 
chronic liver disease. Cases without consent to 
participate in the study were also excluded. 
Statistical analysis 
All statistical analyzes of the data were 
performed by SPSS (15.0 IBM Co., Chicago, 
Illinois, USA) program. The Pearson test was 
used to analyze the correlation coefficients and 
statistical significance between the clinical 
parameters whose normal distribution was 
demonstrated by analytical methods (using 
Kolmogorov Smirnov and Shapiro-Wilk tests). 
Spearman's correlation test was used for the 
relationship between at least one of the 
variables which did not show normal 
distribution or ordinal variables. The statistical 
difference between the independent parameters, 
whose normal distribution was shown by the 
tests mentioned above, was investigated by 
independent groups t test (Student's t test) and 
expressed as mean ± standard deviation. 
Kruskal Wallis test was used to compare the 
data with abnormal distribution and the results 
were expressed as median (min-max). 
Statistical significance level was accepted as p 
<0.05. 
 
Results  
The study population consisted of 31 (51%) 
male and 29 (48%) female patients. The age of  
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Table 1. The clinical and laboratory findings of  
the study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Median value. 
the patients was 60.8 ± 12.4 years. The mean 
GFR value of the CKD patients included in the 
study was 36.3 ± 14.5 ml / min. According to 
CKD stage, 5 (9%) patients were classified as 
stage 2, 31 (51%) patients as stage 3 and 24 
(40%) patients as stage 4 CKD. Twenty-six 
(43%) patients were diagnosed with diabetes 
mellitus (DM) and the mean duration of 
diabetes was 12.0 ± 5.7 years. Nine (85%) 
people were smoking cigarette and 88% (53 
cases) of the patients were using anti-
hypertensive (anti-HT) treatment due to 
hypertension. The clinical and laboratory 
findings of the cases included in the study are 
presented in Table 1. 
The mean NT-pro BNP values of the patients 
included in the study were 1181.1 ± 2198.6 pg 
/ ml and the median value was 473.7  
(min:37,55pg/ml-max: 14541pg / ml). 
There was a positive correlation between NT-
pro BNP levels and urea (r = 0.66, p <0.01), 
creatinine (r = 0.69, p <0.01) and phosphorus 
(r = 0.36, p <0.01) values and then negative 
correlation with hemoglobin (r = -0.32, p = 
0.01), hematocrit (r = -0.36, p <0.01), albumin 
(r = -0.29, p = 0.02) and GFR values (r = -0.35, 
p <0.01). There was no correlation between 
age, height, weight, body mass index (BMI), 
smoking cigarette, use of anti-HT agents, DM 
time, blood pressures, heart rate and other 
laboratory findings and NT-pro BNP levels. 
The results of the analysis showing the 
correlation between NT-pro BNP level and 
clinical and laboratory parameters are shown in 
Table 2. 
 
Discussion 
The most important results of this study were 
that NT Pro BNP had a positive correlation with 
serum creatinine and phosphorus levels, which 
are important markers of renal function, and a 
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negative correlation with hemoglobin, 
hematocrit, albumin and GFR levels. 
 
Table 2. The correlation between NT-pro BNP 
level and clinical and laboratory parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CKD is an important public health problem in 
the world and in our country (1). According to 
the data of the CREDIT study the prevalence of 
CKD from all causes in Turkey was estimated 
at 15.7% [12]. The main problem with this large 
group of patients is the inability to effectively 
control the complications as well as the disease. 
Cardiovascular diseases, commonly seen in 
patients with chronic renal failure, are a major 
cause of morbidity and mortality [1]. 
Cardiovascular diseases seen in CKD have a 
broad spectrum and these are mainly left 
ventricular hypertrophy, ischemic heart 
disease, heart failure, peripheral vascular 
diseases, cardiac arrhythmias and sudden death 
[13]. 
LVH is a strong predictor of mortality in CKD 
[13]. There are many studies in the literature 
that NT-pro BNP is a strong predictor of left 
ventricular hypertrophy. In a study by Satyan et 
al. [4] in asymptomatic HD patients, a 
significant relationship was found between NT-
pro BNP and left ventricular mass index. In 
another study, it was shown that there is a direct 
relationship between NT-pro BNP and left 
ventricular hypertrophy in patients with end-
stage renal disease (ESRD) [5]. Wang et al. [6] 
found that NT-pro BNP levels were 
significantly higher in patients with left 
ventricular dysfunction and severe left 
ventricular hypertrophy in a CKD cohort 
undergoing dialysis treatment. In another study 
performed by the same team, the association of 
NT-pro BNP with cardiovascular congestion, 
mortality and cardiac events was examined in a 
group of 230 patients with chronic peritoneal 
dialysis [7]. In this study, echocardiographic 
measurements were performed concurrently 
with basal NT-pro BNP value and all patients 
were followed up to 3 years. As a result of the 
study, a strong relationship was found between 
left ventricular EF, left ventricular mass index 
                                                        Duman et al.  Exp Biomed Res 2020; 3(1):30-36 
   
 
34 
 
and residual GFR and NT-pro BNP. NT-pro 
BNP has been shown to be an important 
predictor of cardiovascular congestion, 
mortality and cardiovascular side effects.  
Studies have shown that left ventricular 
hypertrophy was detected at the beginning of 
dialysis treatment in more than 70% of CKD 
patients and that the frequency of left 
ventricular hypertrophy increased in this patient 
group over time [14,15]. The positive 
correlation between NT-pro BNP levels and 
urea and creatinine values in our study and the 
negative correlation with GFR support that the 
severity of hypervolemia increases as the CKD 
stage progresses. Deflippe et al. [16] found 
positive and significant correlation between NT 
pro BNP and LVH in asymptomatic 
compensated CKD patients and was consistent 
with GFR. In another study performed on the 
diagnostic values of natriuretic peptides in 
CKD, a negative correlation was found between 
BNP and GFR and it was reported that the 
increase in phosphorus values and anemia-
related values were related to the progression of 
CKD stage [17]. In the evaluation of this group, 
hypoalbuminemia in patients was associated 
with CKD-induced urinary protein loss and 
malnutrition, and its association with natriuretic 
peptides was attributed to extracellular volume 
increase and hypervolemia. In our study, a 
positive correlation was found between the NT-
pro BNP and phosphorus, and a negative 
correlation between NT-pro BNP and 
hemoglobin, hematocrit, albumin values. This 
suggests that as the degree of renal failure 
progresses in compensated CKD, it may show 
increased anemia and metabolic imbalance 
disturbances as well as a reflection of increased 
hypervolemia. In addition, hypoalbuminemia is 
an important indicator of inflammation and 
CRP elevation and hypoalbuminemia in CKD 
are two independent and strong predictors of 
mortality [18, 19]. In a study performed in 
patients with ESRD, it was shown that there 
was a 4.6-fold increase in deaths related to all 
diseases and 5.5-fold increase in CVD-related 
deaths due to the increase in CRP level [20]. 
Studies have shown that inflammation markers 
are significantly reduced in patients with 
euvolemia, where hypervolemia causes 
inflammation and cardiovascular morbidity and 
mortality in CKD patients [18,19]. In our study, 
there was a negative correlation between NT-
pro BNP and albumin, which is consistent with 
the above-mentioned literature. In addition, we 
found a significant relationship between NT-
pro BNP and CRP (p=0.09). However, this 
value was above the level of statistical 
significance. We thought that this might be 
related to the scarcity of our patients. 
Limitations of present study are lack of 
echocardiographic evaluation and relatively 
small study population. However, our results 
showing significant association between NT 
pro BNP and compensated CKD.  
 
Conclusion 
Among the main causes of BNP and NT-pro 
BNP increase in CKD patients are factors such 
as increased extracellular volume, myocardial 
strain and increased left ventricular pressure 
(9). In addition, causes such as left ventricular 
hypertrophy, endothelial dysfunction in 
advanced CKD, systolic and diastolic left 
ventricular insufficiency, and ischemic cardiac 
disease also contribute to this increase. In 
conclusion, BNP and NT-pro BNP are strong 
predictors of all-cause cardiovascular mortality 
in asymptomatic CKD patients. In the light of 
all these data, it is possible to say that NT-pro 
BNP is associated with hypervolemia and 
therefore increased cardiovascular mortality in 
CKD. 
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